Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127332901 | 12733290 | 1 | I | 20160701 | 20160909 | 20160912 | 20160912 | EXP | US-009507513-1609USA005265 | MERCK | 74.00 | YR | M | Y | 63.46000 | KG | 20160912 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127332901 | 12733290 | 1 | PS | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | Oral | TOTAL DAILY DOSE: 140 MG, FREQUENCY: 1 IN 1 D, QD | Y | 21029 | 140 | MG | CAPSULE | QD | |||||
| 127332901 | 12733290 | 2 | SS | GLIADEL | CARMUSTINE | 1 | TOTAL DAILY DOSE: 7.7 MG, UNK | 0 | |||||||||||
| 127332901 | 12733290 | 3 | C | ALLEGRA | FEXOFENADINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 4 | C | AMLODIPINE BESYLATE. | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 5 | C | ASPIRINE | ASPIRIN | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 6 | C | PANTOPRAZOLE SODIUM. | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 7 | C | TRAZODONE HYDROCHLORIDE. | TRAZODONE HYDROCHLORIDE | 1 | 0 | TABLET | |||||||||||
| 127332901 | 12733290 | 8 | C | FLUTICASONE | FLUTICASONEFLUTICASONE PROPIONATE | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 9 | C | LEVETIRACETAM. | LEVETIRACETAM | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 10 | C | ONDANSETRON | ONDANSETRON | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 11 | C | REGLAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127332901 | 12733290 | 12 | C | AMBIEN | ZOLPIDEM TARTRATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127332901 | 12733290 | 1 | Glioblastoma multiforme |
| 127332901 | 12733290 | 2 | Glioblastoma multiforme |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127332901 | 12733290 | HO |
| 127332901 | 12733290 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127332901 | 12733290 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127332901 | 12733290 | 1 | 20160517 | 20160630 | 0 | |
| 127332901 | 12733290 | 2 | 20160505 | 0 |